RxDoctor Payments Data

Sudip Ringwala, DO

Allergy & Immunology · Kenosha, WINPI 1588956197

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 310 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AstraZeneca at 36.7% of the total.

$5,864in general payments, 2019–2025

Across 310 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$814
  • Sanofi$544
  • Takeda Pharmaceuticals U.S.A., Inc.$302
  • Optinose US, Inc.$204
  • Amgen$172
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$5,839100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,864 in reported general payments places this provider in the 85th percentile of 55 allergy & immunology providers in Wisconsin.

See all allergy & immunology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$60,019
Medicare patients
74
Services billed
4,344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab12$43,874
XolairOmalizumab11$31,122
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$28,604
Epinephrine24$4,404
Fluticasone Propionate55$1,099
Albuterol Sulfate HfaAlbuterol Sulfate40$741
Famotidine44$609
Azelastine Hcl16$513
Montelukast Sodium22$253
Pantoprazole Sodium18$228
Levocetirizine Dihydrochloride26$213
Prednisone13$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$814$28,60440 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 55 allergy & immunology providers in Wisconsin.

Other allergy & immunology in Kenosha

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →